Tvardi Therapeutics (TVRD) Cash from Operations (2013 - 2026)
Tvardi Therapeutics (TVRD) posted Cash from Operations of 5900000.0 for Q1 2026, down 3.51% sequentially from 5700000.0 in Q4 2025, and up 23.27% YoY from 4786357.88 in Q1 2025.
Tvardi Therapeutics (TVRD) Cash from Operations (2013 - 2026) Analysis & Trends
Tvardi Therapeutics has reported Cash from Operations for 14 years, with the latest figure at 5900000.0 in Q1 2026.
- Quarterly Cash from Operations rose 23.27% year-over-year to 5900000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 21711000.0 (down 586.9% YoY) and the FY2025 annual result came in at 23500000.0, down 28.38% from the prior year.
- Cash from Operations eased to 5900000.0 in Q1 2026 per TVRD's latest filing, from 5700000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 23636000.0 in Q2 2024 and troughed at 34618000.0 in Q1 2023.
- A 5-year average of 12853705.88 and a median of 7689000.0 in 2025 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations plunged 1788.35% in 2022, then jumped 215.61% in 2024.
- Over 5 years, Cash from Operations stood at 23510000.0 in 2022, then rose by 26.12% to 17370000.0 in 2023, then surged by 72.18% to 4833000.0 in 2024, then slipped by 17.94% to 5700000.0 in 2025, then retreated by 3.51% to 5900000.0 in 2026.
- According to Business Quant data, Cash from Operations over the past three periods registered 5900000.0, 5700000.0, and 4243000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Tvardi Therapeutics | 17.36 Mn | 17.36 Mn | - | -9.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.90 Mn |
| Mar 31, 2026 | -5.90 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Dec 31, 2025 | -5.70 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Sep 30, 2025 | -4.24 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Jun 30, 2025 | -5.87 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Mar 31, 2025 | -7.69 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Dec 31, 2024 | -4.83 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Sep 30, 2024 | -6.66 Mn |
| Jun 30, 2024 | 23.64 Mn |
| Jun 30, 2024 | 23.64 Mn |
| Mar 31, 2024 | -30.45 Mn |
| Mar 31, 2024 | -30.45 Mn |
| Dec 31, 2023 | -17.37 Mn |
| Dec 31, 2023 | -17.37 Mn |